Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) - Episode 11

Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations


Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.